The healthcare costs of antimicrobial resistance in Lebanon: a multi-centre prospective cohort study from the payer perspective

K. Iskandar*, C. Roques, S. Hallit, R. Husni-Samaha, N. Dirani, R. Rizk, R. Abdo, Y. Yared, M. Matta, I. Mostafa, R. Matta, P. Salameh, L. Molinier

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Our aim was to examine whether the length of stay, hospital charges and in-hospital mortality attributable to healthcare- and community-associated infections due to antimicrobial-resistant bacteria were higher compared with those due to susceptible bacteria in the Lebanese healthcare settings using different methodology of analysis from the payer perspective.

Methods: We performed a multi-centre prospective cohort study in ten hospitals across Lebanon. The sample size consisted of 1289 patients with documented healthcare-associated infection (HAI) or community-associated infection (CAI). We conducted three separate analysis to adjust for confounders and time-dependent bias: (1) Post-HAIs in which we included the excess LOS and hospital charges incurred after infection and (2) Matched cohort, in which we matched the patients based on propensity score estimates (3) The conventional method, in which we considered the entire hospital stay and allocated charges attributable to CAI. The linear regression models accounted for multiple confounders.

Results: AIs and CAIs with resistant versus susceptible bacteria were associated with a significant excess length of hospital stay (2.69 days [95% CI,1.5-3.9]; p < 0.001) and (2.2 days [95% CI,1.2-3.3]; p < 0.001) and resulted in additional hospital charges ($1807 [95% CI, 1046-2569]; p < 0.001) and ($889 [95% CI, 378-1400]; p = 0.001) respectively. Compared with the post-HAIs analysis, the matched cohort method showed a reduction by 26 and 13% in hospital charges and LOS estimates respectively. Infections with resistant bacteria did not decrease the time to in-hospital mortality, for both healthcare- or community-associated infections. Resistant cases in the post-HAIs analysis showed a significantly higher risk of in-hospital mortality (odds ratio, 0.517 [95% CI, 0.327-0.820]; p = 0.05).

Conclusion: his is the first nationwide study that quantifies the healthcare costs of antimicrobial resistance in Lebanon. For cases with HAIs, matched cohort analysis showed more conservative estimates compared with post-HAIs method. The differences in estimates highlight the need for a unified methodology to estimate the burden of antimicrobial resistance in order to accurately advise health policy makers and prioritize resources expenditure.

Original languageEnglish
Article number404
Number of pages12
JournalBMC Infectious Diseases
Volume21
Issue number1
DOIs
Publication statusPublished - 1 May 2021

Keywords

  • Antimicrobial resistance
  • Healthcare cost
  • Length of stay
  • In-hospital mortality
  • LENGTH-OF-STAY
  • LACTAMASE-PRODUCING ENTEROBACTERIACEAE
  • STAPHYLOCOCCUS-AUREUS INFECTIONS
  • HOSPITAL-ACQUIRED INFECTIONS
  • TIME-DEPENDENT BIAS
  • ANTIBIOTIC-RESISTANCE
  • ESCHERICHIA-COLI
  • KLEBSIELLA-PNEUMONIAE
  • METHICILLIN-RESISTANT
  • ECONOMIC BURDEN

Cite this